Caris MI Clarity
Breast Cancer Recurrence Testing
Early Access Opportunity
Partner with Caris to advance cancer care and improve patient outcomes through the Caris MI Clarity™ Early Access Program. This initiative provides a select group of oncologists with the opportunity to evaluate a next-generation prognostic tool that leverages multimodal AI technology and computational pathology to deliver rapid, clinically actionable results for HR+/HER2−, postmenopausal, node-negative early-stage breast cancer patients.
During this early access period, which runs through the end of June, participating providers can utilize the tests and will be asked to complete a brief feedback survey. This is a unique chance to be among the first to experience and shape the future of breast cancer prognostics with Caris.
Get Early Access
Why MI Clarity?
Treatment decisions in early-stage breast cancer are often made without full visibility into long-term recurrence risk. But what if both windows of risk — early and late — were clear before the first treatment decision?
Caris has a new approach to prognostic assessment in early-stage breast cancer. Caris MI Clarity provides clarity at diagnosis and confidence for the path forward.
Caris MI Clarity is a multimodal, multitask deep learning AI model for breast cancer recurrence risk. No genomic sequencing required
Analyzes digitized H&E whole slide images combined with clinical inputs to stratify patients into low- and high-risk categories for both early (Years 0–5) and late (Years 5–15) distant recurrence
Supported by robust clinical data from the TAILORx and NSABP B-42 trials, Caris MI Clarity offers more precise risk stratifications — with a turnaround time of just 1-3 days
See the Full Horizon. Plan
the Journey Ahead.
- Reports two independent distant recurrence risks: early window (Years 0-5) and late window (Years 5-15)
- One test at diagnosis
Thoroughly Validated.
Expanding to Serve More
Patients.
- Trained and validated on TAILORx1 and NSABP B-422 data
- Landmark trials behind today’s standard of care
- Actively expanding evidence base to cover more patients
Faster Results, Lower Cost, Broader Access.
- 1-3 days turnaround from qualified sample receipt vs. up to 14 days for standard genomic sequencing tests
The Evidence Behind the Clarity
Abstract RF3-07: A Multimodal-Multitask Deep Learning Model Trained…
February 17 2026
Clarity BCR is a multimodal-multitask (MMMT) deep learning algorithm developed to estimate late distant recurrence (DR) risk in hormone receptor–positive (HR+) breast cancer and to identify patients likely to benefit from extended endocrine therapy (EET)…
Abstract GS1-08: Multimodal artificial intelligence (AI) models integrating image…
February 17 2026
TheTAILORx trial established that adjuvant endocrine therapy (ET) is non-inferiorto chemotherapy plus ET (CET) in T1-2N0 HR+/HER2-negative early breast cancer(EBC) with an Oncotype DX (ODX) 21-gene recurrence score (RS) of 11-25, RS 0-10is associated with…
ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration…
February 17 2026
Clarity BCR is a multimodal-multitask (MMMT) deep learning algorithm developed to estimate late distant recurrence (DR) risk in hormone receptor–positive (HR+) breast cancer and to identify patients likely to benefit from extended endocrine therapy (EET)…
1 Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Jr., Dees, E. C., Goetz, M. P., Olson, J. A., Jr., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., Ravdin, P. M., . . . Sledge, G. W., Jr. (2018). Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med, 379(2), 111-121. https://doi.org/10.1056/NEJMoa1804710
2 Mamounas, E. P., Bandos, H., Rastogi, P., Lembersky, B. C., Jeong, J. H., Geyer, C. E., Jr., Fehrenbacher, L., Chia, S. K., Brufsky, A. M., Walshe, J. M., Soori, G. S., Dakhil, S. R., Wade, J. L., 3rd, McCarron, E. C., Swain, S. M., & Wolmark, N. (2023). Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer. J Natl Cancer Inst, 115(11), 1302-1309. https://doi.org/10.1093/jnci/djad078
Discover
More
MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors.
Caris Assure® is a minimally invasive blood test that provides comprehensive molecular analysis of tumor biomarkers when tumor tissue is not feasible.